GlassScriptPhysician profile
Susan Grumbach
NPI 1831465624
$7,649.96
in general payments reported to CMS, 2019-2025
42 companies · $1,759 in 2025
The $1,759 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,376 · 2022: $1,427 · 2023: $1,626 · 2024: $1,461 · 2025: $1,759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,767 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,766.73 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,081.30 | 2021-2025 | |
| Novo Nordisk INC | $921.65 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $634.97 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $509.52 | 2021-2025 | |
| Amgen INC. | $504.51 | 2021-2025 | Otezla, Repatha, Otezla |
| Glaxosmithkline, LLC. | $423.01 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $396.73 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Abbott Laboratories | $345.49 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $322.04 | 2021-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $301.40 | 2021-2025 | Trintellix |
| Insulet Corporation | $239.44 | 2021-2025 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $214.93 | 2021-2025 | Jardiance |
| Astellas Pharma US INC | $174.15 | 2023-2024 | Veozah |
| Teva Pharmaceuticals USA, INC. | $147.99 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $142.51 | 2021-2023 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $123.68 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $120.92 | 2022 | |
| Xeris Pharmaceuticals, INC. | $120.29 | 2022-2023 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $115.71 | 2021-2025 | Capvaxive, Steglatro, Belsomra |
| Antares Pharma, INC. | $99.39 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Daiichi Sankyo INC. | $87.06 | 2022-2025 | Injectafer |
| Dexcom, INC. | $78.96 | 2021-2025 | Dexcom G6 Transmitter |
| Eisai INC. | $60.36 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $56.37 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $42.73 | 2021-2023 | Xarelto |
| Axsome Therapeutics, INC. | $39.59 | 2025 | Auvelity |
| Boston Scientific Corporation | $33.42 | 2025 | Watchman Access System |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.15 | 2024-2025 | Caplyta |
| Sumitomo Pharma America, INC. | $29.60 | 2025 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $28.77 | 2025 | Voquezna |
| Halozyme INC | $27.49 | 2023 | |
| Verity Pharmaceuticals INC. | $22.50 | 2025 | Tlando |
| Otsuka America Pharmaceutical, INC. | $22.37 | 2025 | Rexulti |
| Alnylam Pharmaceuticals INC. | $19.94 | 2022 | |
| Therapeuticsmd, INC. | $19.26 | 2022 | |
| Esperion Therapeutics, INC. | $17.50 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $16.38 | 2022 | |
| Corcept Therapeutics | $16.30 | 2025 | Korlym |
| Supernus Pharmaceuticals, INC. | $16.09 | 2024 | Xyosted, Qelbree, Tlando |
| Tris Pharma INC | $14.81 | 2025 | Dyanavel Xr |
| Tolmar, INC. | $14.80 | 2024 | |
| Bausch Health US, LLC | $12.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Grumbach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.